Zhiwei Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhiwei Xu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Haijian Wu
Taizhou Municipal Hospital (Taizhou University Affiliated Municipal Hospital), Taizhou University
2 shared publicationsCaidi He
Taizhou Municipal Hospital (Taizhou University Affiliated Municipal Hospital), Taizhou University
1 shared publicationDi Ye
Taizhou Municipal Hospital (Taizhou University Affiliated Municipal Hospital), Taizhou University
1 shared publication- Dongguo Wang
Department of Central Laboratory, Taizhou Municipal Hospital Affiliated with Taizhou University, Taizhou, Zhejiang, China
1 shared publication Qianyin Zheng
Department of Ophthalmology Taizhou Municipal Hospital Affiliated with Taizhou University Taizhou Zhejiang China
1 shared publication- Ruiyuan Chen
Taizhou University
1 shared publication
Latest Publications
- 26 September 2026
- Published by Taylor & Francis in Biological Rhythm Research
- p. 1-13
Association of late bedtime and glycemic control with diabetic retinopathy in adults with diabetes: a population-based study
1. Diabetic retinopathy (DR) is a frequent microvascular complication of diabetes and remains a leading cause of vision loss among people with diabetes (Cheung et al. 2010; Yau et al. 2012). After ...
- 26 September 2026
- Published by Taylor & Francis in Biological Rhythm Research
- p. 1-13
Association of late bedtime and glycemic control with diabetic retinopathy in adults with diabetes: a population-based study
1. Diabetic retinopathy (DR) is a frequent microvascular complication of diabetes and remains a leading cause of vision loss among people with diabetes (Cheung et al. 2010; Yau et al. 2012). After ...
- 16 September 2021
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 16 (1) , 2100016
Integrating SWATH‐MS proteomics and transcriptome analysis to preliminarily identify three DEGs as biomarkers for proliferative diabetic retinopathy
Purpose: We intended to preliminarily find differentially expressed proteins that play crucial roles in proliferative diabetic retinopathy (PDR), and lay the foundation for subsequent further research on the mechanism.Experimental Design: Here, we developed a new strategy integrated the sequential windowed acquisition of all theoretical fragment ion (SWATH) mass spectra (MS) with multi‐dataset joint analysis to screen for the PDR plasma biomarker. The annotation of the given gene list was performed with ClueGO function analysis. Additionally, the protein–protein interaction relationship was also revealed by the STRING database.Results: In SWATH‐MS assays, we identified 23 upregulated and 13 downregulated proteins in PDR plasma. In the mRNA database analysis, 375 genes were identified as differentially expressed genes in GSE102485. Only three genes (FCGR3A, DPEP2, and ADGRF5) were characterized as upregulated in both the dataset and the SWATH‐MS list. The area under the ROC curve (AUC) of FCGR3A, DPEP2, and ADGRF5 in distinguishing PDR from others was 0.739, 0.770, and 0.739.Conclusions and Clinical Relevance: We provide a novel strategy for biomarker screening and identified plasma FCGR3A, DPEP2, and ADGRF5 as potential biomarkers for patients with PDR. Identifying the key molecules of the disease is essential for the development of new therapeutic molecules and new uses of existing drugs.
- 16 September 2021
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 16 (1) , 2100016
Integrating SWATH‐MS proteomics and transcriptome analysis to preliminarily identify three DEGs as biomarkers for proliferative diabetic retinopathy
Purpose: We intended to preliminarily find differentially expressed proteins that play crucial roles in proliferative diabetic retinopathy (PDR), and lay the foundation for subsequent further research on the mechanism.Experimental Design: Here, we developed a new strategy integrated the sequential windowed acquisition of all theoretical fragment ion (SWATH) mass spectra (MS) with multi‐dataset joint analysis to screen for the PDR plasma biomarker. The annotation of the given gene list was performed with ClueGO function analysis. Additionally, the protein–protein interaction relationship was also revealed by the STRING database.Results: In SWATH‐MS assays, we identified 23 upregulated and 13 downregulated proteins in PDR plasma. In the mRNA database analysis, 375 genes were identified as differentially expressed genes in GSE102485. Only three genes (FCGR3A, DPEP2, and ADGRF5) were characterized as upregulated in both the dataset and the SWATH‐MS list. The area under the ROC curve (AUC) of FCGR3A, DPEP2, and ADGRF5 in distinguishing PDR from others was 0.739, 0.770, and 0.739.Conclusions and Clinical Relevance: We provide a novel strategy for biomarker screening and identified plasma FCGR3A, DPEP2, and ADGRF5 as potential biomarkers for patients with PDR. Identifying the key molecules of the disease is essential for the development of new therapeutic molecules and new uses of existing drugs.